23:01 , Jun 22, 2018 |  BC Extra  |  Preclinical News

Alzheimer's disease linked to herpesvirus

Researchers from the Icahn School of Medicine at Mount Sinai and colleagues found traces of mild strains of herpesvirus in the brains of patients with Alzheimer's disease, adding evidence to previous theories that some viruses...
00:35 , Oct 21, 2017 |  BioCentury  |  Product Development

Naked ambition

Proof-of-concept data from miRagen Therapeutics Inc. show systemic delivery of its lead candidate can shrink lesions in cutaneous T cell lymphoma, and that its oligonucleotide platform can achieve broad distribution and a long half-life without...
15:15 , Oct 20, 2017 |  BC Week In Review  |  Clinical News

miRagen reports Phase I data of systemic microRNA therapy in CTCL

miRagen Therapeutics Inc. (NASDAQ:MGEN) reported interim data from 23 evaluable patients with mycosis fungoides-type cutaneous T cell lymphoma (CTCL) in the second part of an open-label, U.S Phase I trial showing that once-weekly 300, 600...
21:25 , Oct 13, 2017 |  BC Extra  |  Clinical News

miRagen reports systemic microRNA therapy data in CTCL

miRagen Therapeutics Inc. (NASDAQ:MGEN) reported interim data from the second part of an ongoing Phase I trial of MRG-106 in patients with mycosis fungoides-type cutaneous T cell lymphoma (CTCL). Among 23 patients receiving the systemically...
23:21 , Nov 3, 2016 |  BC Week In Review  |  Company News

Signal, miRagen deal

miRagen will merge with Signal to form a publicly traded microRNA company focused on hematological malignancies, pathological fibrosis and cardiovascular and neurodegenerative diseases. The surviving entity will retain miRagen's name and trade on NASDAQ. The...
23:20 , Nov 1, 2016 |  BC Extra  |  Company News

miRagen finds public path via Signal merger

miRagen Therapeutics Inc. (Boulder, Colo.) will merge with Signal Genetics Inc. (NASDAQ:SGNL) to form a publicly traded microRNA company focused on hematological malignancies, pathological fibrosis and cardiovascular and neurodegenerative diseases. The surviving entity will retain...
07:00 , Sep 22, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Protein kinase B (AKT; AKT1; PKB; PKBA); microRNA-155 (miR-155)

Infectious disease INDICATION: Leishmaniasis Cell culture and mouse studies suggest inhibiting the miR-155/AKT signaling pathway could help treat a virulent subtype of leishmaniasis. In mouse bone marrow macrophages, a strain of Leishmania guyanensis that naturally harbors a...
08:00 , Mar 7, 2016 |  BC Week In Review  |  Clinical News

MRG-106: Phase I started

miRagen began an open-label, U.S. Phase I trial of MRG-106 in about 25 patients. The first part will evaluate up to 5 intratumoral injections of MRG-106 over up to 15 days and determine the dose...
08:00 , Feb 18, 2016 |  BC Innovations  |  Product R&D

Crossing paths

Selina Koch, Staff Writer  With its first foray into the brain, Catabasis Pharmaceuticals Inc. is using its linker technology to simultaneously target the inflammatory and oxidative stress pathways that drive neurodegeneration, starting with amyotrophic lateral sclerosis...
02:25 , Nov 11, 2015 |  BC Extra  |  Financial News

miRagen raises $41 series C

MicroRNA company miRagen Therapeutics Inc. raised $41 million in a series C round co-led by MRL Ventures and JAFCO. Other new investors Brace Pharma Capital and MP Healthcare Venture Management joined existing investors Atlas Venture,...